Zdrowie i gospodarka · 25.05.1994
Prospective Grant Of Partially Exclusive Licenses: Antisense Phosphorothioate Oligodeoxyribonucleotides
The National Institutes of Health (NIH) intends to grant partially exclusive licenses to ISIS Pharmaceuticals, Inc. and Hybridon, Inc. for antisense phosphorothioate oligodeoxyribonucleotides patent applications and patents.